Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs

A compound selected from the group consisting of:

• wherein n is 8 or 9 and R1 is selected from the group consisting of 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6) pivaloyl 7)formyl 8) propionyl 9) butryl ) 10) valeryl 11) isovaleryl 12) stearoyl 13) myristoyl 14) palmitoyl 15) oleoyl 16) benzoyl 17) lauroyl, 18) 2-oxopropyl 19) 2-oxopentyl 20) 3-methyl-2-oxobutyl 21) amino 22) carbethoxyl amino 23) 2-hydroxypropyl 24) retinol acetate;
• wherein the compound is all-trans or a 5-cis form or a mixture of these two isomers and R3 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl and 24) 2-hydroxypropyl;
• wherein the compound is all-trans or a 5-cis form or a mixture of these two isomers and R4 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl and 24) 2-hydroxypropyl;
• wherein the compound is all-trans or a 5-cis form or mixture of these two isomers and R5 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound is all-trans or a 5-cis form or a mixture of these two isomers and R6 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound is all-trans or a 5-cis form or a mixture of these two isomers and R7 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound is all-trans or a 5-cis form or a mixture of these two isomers and R8 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein R9 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl and 24) 2-hydroxypropyl;
• wherein R10 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl and 24) 2-hydroxypropyl;
• wherein n is 2, 3, or 4 and the repeating units can be in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units can be in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units can be in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units can be in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units can be in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units can be in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n=2, 3, 4, 5, 6, 8, or 9 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 4, 5, 6, 8, or 9 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 4, 5, 6, 8, or 9 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 4, 5, 6, 8, or 9 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 4, 5, 6, 8, or 9 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 2, 3, 4, 5, 6, 8, or 9;
• wherein n is 2, 3, 4, 5, 6, 8, or 9;
• wherein n is 2, 3, 4, 5, 6, 8, or 9;
• wherein the compound is all-trans or a 5-cis form or a mixture of these two isomers and R11 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein n is 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein n is 1, 2, 3, or 4 and the repeating units are in any reduced or oxidized form;
• wherein R12 is hydrogen or a hydroxyl group;
• wherein R13 is hydrogen or a hydroxyl group;
• wherein R14 is hydrogen or a hydroxyl group;
• wherein R15 is hydrogen or a hydroxyl group;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R,6 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and RI7 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R18 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R19 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R20 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R21 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R22 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R23 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl;
• and
• wherein the compound contains 0, 1, 2, 3, 4, 5, 6, 7, or 8 methyl groups and R24 is selected from the group consisting of:
• 1) acetone, 2) ethyl, 3) hydroxyalkyl 4) amine 5) hydroxyl 6)formyl 7) propionyl 8) butryl ) 9) 2-oxopropyl 10) 2-oxopentyl 11) retinol acetate 12) stearoyl 12) myristoyl 13) valeryl 14) isovaleryl 15) pivaloyl 16) palmitoyl 17) oleoyl 18) benzoyl 19) lauroyl 20) stearoyl 21) amino 22) carbethoxyl amino 23) 3-methyl-2-oxobutyl 24) and 2-hydroxypropyl.

A method of treating a disease selected from the group consisting of:

• inflammatory and immune injury, glomerulonephritis, autoimmune disease, rheumatoid arthritis, hepatitis, chronic inflammatory disease, stroke, inflamed rheumatoid joint;
• iron overload, idiopathic haemochromatosis, alcohol-related iron overload, disorders of premature ageing, lead poisoning, malaria, sickle cell anaemia, emphysema, ARDS (Adult Respiratory Syndrome), cardiac iron overload, neuromuscular disorders, cataract, retinopathy, UV radiation damage to skin, contact dermatitis;
• tumors, diabetes, hyperglycaemia, diabetic retinopathy, peripheral neuropathy, type II or non-insulin-dependent diabetes, juvenile onset diabetes, and cystic fibrosis, comprising administering a therapeutically effective amount of a compound the formula:
• to an individual.